2016 Q2 Financial Review

Unimicron

July 28th, 2016

Disclaimer

- Except for statements in respect of historical matters, the statements in this release are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual performance, financial condition or results of operations of Unimicron to be materially different from what may be implied by such forward-looking statements.
- The financial forecasts and forward-looking statements in this release reflect the current belief of Unimicron as of the date of this release and Unimicron undertakes no obligation to update these forecasts and forward-looking statements for events or circumstances that occur subsequent to such date.
- The statements in respect of historical matters may contain unaudited information, which may have certain deficiency or weakness so as not to fairly present financial condition or the result of operations of Unimicron.

CONFIDENTIA



Consolidated Statements of Comprehensive Income – QoQ

	Q2-16	%	Q1-16	%	NTD:M
	(Unreviewe		(Reviewed	QoQ %	
Net Sales	14,992	100.0	15,328	100.0	(2)
Cost of sales	(13,942)	(93.0)	(13,867)	(90.5)	1
Gross Profit	1,050	7.0	1,461	9.5	(28)
Operating Expenses	(1,374)	(9.1)	(1,401)	(9.1)	(2)
Other Income and Expenses	82	0.5	(9)	(0.1)	1011
Operating Income (Loss)	(242)	(1.6)	51	0.3	(575)
Net Non-operating Income and Expenses	37	0.2	(206)	(1.3)	118
Income (Loss) before tax	(205)	(1.4)	(155)	(1.0)	(32)
Income Tax (Expense) Benefit	(0)	(0.0)	(76)	(0.5)	(100)
Net Income (Loss)	(205)	(1.4)	(231)	(1.5)	11
Other Comprehensive Income and Losses	(499)	(3.3)	(162)	(1.1)	(208)
Comprehensive Income (Loss)	(704)	(4.7)	(393)	(2.6)	(79)
Net Income (Loss) Attributable to:					
Shareholders of the Parent	(197)	(1.3)	(218)	(1.4)	
Non-controlling Interests	(8)	(0.1)	(13)	(0.1)	
Net Income (Loss)	(205)	(1.4)	(231)	(1.5)	
EBITDA	2,076		2,132		
%(Sales)	14%		14%		
EPS (Basic)	(0.13)		(0.15)		
(Diluted)	(0.13)		(0.15)		

CONFIDENTIAL

Unimicron

Consolidated Balance Sheets

	2016		2016		2015	NTD:M
	Jun.30	%	Mar.31	%	Jun.30	%
	(Unreviewed)	(Reviewed)		(Reviewed)		
Cash	23,015	23.4	23,618	23.6	22,235	21.7
Accounts Receivable	12,284	12.5	11,963	12.0	14,455	14.1
Inventories	4,963	5.1	4,922	4.9	5,100	5.0
Other Current Assets	2,014	2.1	1,843	1.8	2,265	2.2
Long-term Investments	5,838	5.9	5,941	5.9	5,313	5.2
Fixed Assets & Investment Property	48,237	49.1	49,964	50.0	51,328	50.1
Total Assets	98,242	100.0	100,017	100.0	102,400	100.0
Short-term Loans	8,251	8.4	8,617	8.6	11,751	11.5
Long-term Liabilities-Current	5,067	5.2	4,077	4.1	2,709	2.6
Other Current Liabilities	14,511	14.8	14,097	14.1	17,059	16.7
Long-term Liabilities	22,511	22.9	24,053	24.0	22,382	21.9
Shareholders' Equity	46,260	47.1	47,498	47.5	47,073	46.0
Net Inventory						
Turnover Days	34		34		35	
Net Accounts Receivable						
Turnover Days	79		77		91	

Unimicron

CONFIDENTIAL

6

謝謝您的聆聽

Unimicron

Thank you